-
Can GSK’s ViiV Healthcare Deliver Twice-Yearly HIV Therapy?
26 Feb 2026 19:17 GMT
… candidate for ultra long-acting HIV therapy.
VH499, an investigational capsid … status quo and help make HIV treatment a smaller, less frequent … and Senior Vice President at ViiV Healthcare.
-
GSK's ViiV confirms staying power of long-acting HIV treatment Cabenuva in adolescents
26 Feb 2026 23:05 GMT
… GSK’s HIV unit ViiV Healthcare grapples with a new rival in the injectable HIV … the International Maternal Pediatric Adolescent AIDS Clinical Trials Network (IMPAACT).
A … testing lenacapavir in the broader HIV population, ViiV is sharpening the case …
-
ViiV’s four-monthly HIV drug maintains viral suppression at 12 months
26 Feb 2026 18:10 GMT
ViiV Healthcare’s investigational four-monthly HIV drug maintains viral suppression at … of R&D at ViiV Healthcare, said: “These positive 12-month … living with HIV on stable therapy.
ViiV, majority owned by GSK, with Pfizer and …
-
ViiV Healthcare presents pipeline data for two investigational HIV treatment therapies with potential for twice-yearly dosing
25 Feb 2026 19:06 GMT
… : GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer … deeper and broader interest in HIV and AIDS than any company has …
-
ViiV Healthcare reports positive 12-month data showing investigational bNAb lotivibart (N6LS) maintains high levels of viral suppression in long-acting HIV treatment regimen
25 Feb 2026 19:06 GMT
… : GSK) announced that ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer … deeper and broader interest in HIV and AIDS than any company has …
-
HIV studies call for Africa-specific data to optimise treatment strategies
26 Feb 2026 11:03 GMT
… urgently addressed to strengthen HIV treatment strategies across Africa … older people living with HIV, including kidney disease, … study received funding from ViiV Healthcare. All studies were … Health through the National AIDS and STI Control Programme …
-
DOR/ISL Phase III data underlines trend for shift towards two-drug STRs in HIV
25 Feb 2026 23:55 GMT
… III study in adults with HIV who were previously virologically suppressed … an integrase-sparing alternative to ViiV Healthcare’s Dovato, one of the …
-
ViiV Healthcare data show lower rates of steatotic liver disease after switching to Dovato
24 Feb 2026 14:02 GMT
… ‑drug and 3‑drug HIV regimens
ViiV Healthcare has announced new 96 … HIV.
Jean van Wyk, MBChB, MFPM, Chief Medical Officer at ViiV Healthcare, said: “ViiV Healthcare … has led innovation in HIV by developing …
-
GSK grows pipeline with 35Pharma takeover, Frontier deal
25 Feb 2026 14:04 GMT
… the first made by GSK under new chief executive Luke … preserved ejection fraction (HFpEF).
GSK said that HS235 could … multiple kidney diseases."
GSK has global rights to the … patent cliff in HIV medicines sold through its ViiV Healthcare subsidiary – …
-
Drug Resistant Virus Treatment Market Forecast 2026–2036: Market to Reach USD 28.6 Billion by 2036 at 8.4% CAGR
27 Feb 2026 11:57 GMT
… testing and resistance profiling in HIV and hepatitis care are increasing … players include Gilead Sciences, ViiV Healthcare, Merck & Co., Pfizer, Roche, AbbVie, Astellas … disease limits standard regimens, spanning HIV (drug-resistant), HBV (treatment- …
About
© 1995-2026